Optimizing transfusion strategies in damage control resuscitation: Current insights

Journal of Blood Medicine

Volumn 9, Issue , 2018, Pages 117-133

  Pohlman, Timothy H ^a   Fecher, Alison M ^a   Arreola Garcia, Cecivon ^b  

^a Lutheran Hospital Fort Wayne   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Coagulopathy; Fibrinolysis; Hemorrhage; Resuscitation; Shock; Transfusion; Trauma

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; CARBOXYPEPTIDASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; FIBRIN; FIBRINOGEN; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR; WARFARIN;

ACIDOSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; FIBRINOLYSIS; HEART ARREST; HEART INFARCTION; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOCOAGULABILITY; HYPOTENSION; HYPOTHERMIA; HYPOXIA; INFLAMMATION; INJURY; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PROTHROMBIN TIME; REPERFUSION INJURY; RESUSCITATION; REVIEW; RISK FACTOR; SEPSIS; SIGNAL TRANSDUCTION; TERMINAL DISEASE; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOSIS; TRAUMATIC BRAIN INJURY;

EID: 85059010563     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S165394     Document Type: Review

References (182)

1. Pohlman TH, Walsh M, Aversa J, Hutchison EM, Olsen KP, Lawrence Reed R. Damage control resuscitation. Blood Rev. 2015;29(4):251–262.
2. Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood. 2016;128(8):1043–1049.
3. MacLeod JB, Winkler AM, McCoy CC, Hillyer CD, Shaz BH. Early trauma induced coagulopathy (ETIC): prevalence across the injury spectrum. Injury. 2014;45(5):910–915.
4. Schochl H, Schlimp CJ, Voelckel W. Potential value of pharmacological protocols in trauma. Curr Opin Anaesthesiol. 2013;26(2):221–229.
5. Oshiro A, Yanagida Y, Gando S, Henzan N, Takahashi I, Makise H. Hemostasis during the early stages of trauma: comparison with disseminated intravascular coagulation. Crit Care. 2014;18(2):R61.
6. Chang R, Holcomb JB. Optimal fluid therapy for traumatic hemorrhagic shock. Crit Care Clin. 2017;33(1):15–36.
7. Rahbar E, Fox EE, del Junco DJ, et al. Early resuscitation intensity as a surrogate for bleeding severity and early mortality in the PROMMTT study. J Trauma Acute Care Surg. 2013;75(1 Suppl 1):S16–23.
8. Rahbar MH, del Junco DJ, Huang H, et al. A latent class model for defining severe hemorrhage: experience from the PROMMTT study. J Trauma Acute Care Surg. 2013;75(1 Suppl 1):S82–88.
9. Oldroyd JC, Venardos KM, Aoki NJ, et al. Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology. BMC Res Notes. 2016;9(1):457.
10. Levi M, Fries D, Gombotz H, et al. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang. 2011;101(2):154–174.
11. Savage SA, Zarzaur BL, Croce MA, Fabian TC. Redefining massive transfusion when every second counts. J Trauma Acute Care Surg. 2013;74(2):396–400.
12. Brohi K, Cohen MJ, Ganter MT, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64(5):1211–1217.
13. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127–1130.
14. Hess JR, Dutton RB, Holcomb JB, Scalea TM. Giving plasma at a 1:1 ratio with red cells in resuscitation: who might benefit? Transfusion. 2008;48(8):1763–1765.
15. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307–310.
16. McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. J Trauma. 2008;64(2 Suppl):S57–S63.
17. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma. 2008;64(6):1459–1463.
18. Mesar T, Larentzakis A, Dzik W, Chang Y, Velmahos G, Yeh DD. Association between ratio of fresh frozen plasma to red blood cells during massive transfusion and survival among patients without traumatic injury. JAMA Surg. 2017;152(6):574–580.
19. Farooq N, Galiatsatos P, Aulakh JK, Higgins C, Martinez A. Massive transfusion practice in non-trauma related hemorrhagic shock. J Crit Care. 2018;43:65–69.
20. American College of Obstetricians and Gynecologists Committee on Patient Safety and Quality Improvement. Committee Opinion No. 590: preparing for clinical emergencies in obstetrics and gynecology. Obstet Gynecol. 2014;123(3):722–725.
21. Weisbrod AB, Sheppard FR, Chernofsky MR, et al. Emergent management of postpartum hemorrhage for the general and acute care surgeon. World J Emerg Surg. 2009;4:43.
22. Matsumoto T, Nogami K, Shima M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost. 2013;110(4):761–768.
23. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958–965.
24. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381–1389.
25. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21(3):131–142.
26. Huang CC, Shih CC, Liu TY, Lee PY. Assessing the viscoelastic properties of thrombus using a solid-sphere-based instantaneous force approach. Ultrasound Med Biol. 2011;37(10):1722–1733.
27. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24(8):1374–1383.
28. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934–2943.
29. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler ThrombVasc Biol. 2016;36(1):9–14.
30. Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost. 2015;13(Suppl 1):S200–S207.
31. Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015;19:72.
32. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013;304(12):H1585–H1597.
33. Christiaans SC, Wagener BM, Esmon CT, Pittet JF. Protein C and acute inflammation: a clinical and biological perspective. Am J Physiol Lung Cell Mol Physiol. 2013;305(7):L455–L466.
34. Schedin-Weiss S, Richard B, Olson ST. Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes. Arch Biochem Biophys. 2010;504(2):169–176.
35. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115(4):712–728.
36. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 2002;46(2):131–134.
37. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278(51):51059–51067.
38. Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LL. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood. 2007;109(5):1992–1997.
39. Weng HB, Li S. Early changes of plasma angiopoietin-2 in patients with multiple trauma. World J Emerg Med. 2011;2(4):287–290.
40. Daly C, Qian X, Castanaro C, et al. Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor. Sci Rep. 2018;8(1):505.
41. Lomas-Neira J, Venet F, Chung CS, Thakkar R, Heffernan D, Ayala A. Neutrophil-endothelial interactions mediate angiopoietin-2-associated pulmonary endothelial cell dysfunction in indirect acute lung injury in mice. Am J Respir Cell Mol Biol. 2014;50(1):193–200.
42. Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res. 2003;92(6):630–636.
43. Tadros A, Hughes DP, Dunmore BJ, Brindle NP. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood. 2003;102(13):4407–4409.
44. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med. 2014;42(3):691–700.
45. Zinter MS, Spicer A, Orwoll BO, et al. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol. 2016;310(3):L224–L231.
46. Herrero R, Sanchez G, Lorente JA. New insights into the mechanisms of pulmonary edema in acute lung injury. Ann Transl Med. 2018;6(2):32.
47. Hajjarian Z, Tripathi MM, Nadkarni SK. Optical Thromboelas-tography to evaluate whole blood coagulation. J Biophotonics. 2015;8(5):372–381.
48. Johansson PI. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anaesthesiol. 2012;25(2):235–241.
49. Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for peri-operative management. Transfus Med Rev. 2014;28(3):107–113.
50. Weisel JW. Biophysics. Enigmas of blood clot elasticity. Science. 2008;320(5875):456–457.
51. Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med. 2009;17:45.
52. Johansson PI, Svendsen MS, Salado J, Bochsen L, Kristensen AT. Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days. Vox Sang. 2008;94(2):113–118.
53. Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg. 2004;99(5):1440–1444.
54. Gonzalez E, Moore EE, Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care Clin. 2017;33(1):119–134.
55. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263(6):1051–1059.
56. Harr JN, Moore EE, Chin TL, et al. Viscoelastic hemostatic fibrinogen assays detect fibrinolysis early. Eur J Trauma Emerg Surg. 2015;41(1):49–56.
57. Moore EE, Moore HB, Gonzalez E, et al. Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid. J Trauma Acute Care Surg. 2015;78(6 Suppl 1):S65–S69.
58. Wada T. Coagulofibrinolytic changes in patients with post-cardiac arrest syndrome. Front Med (Lausanne). 2017;4:156.
59. Ramsey MT, Fabian TC, Shahan CP, et al. A prospective study of platelet function in trauma patients. J Trauma Acute Care Surg. 2016;80(5):726–732.
60. Davis PK, Musunuru H, Walsh M, et al. Platelet dysfunction is an early marker for traumatic brain injury-induced coagulopathy. Neurocrit Care. 2013;18(2):201–208.
61. Windelov NA, Sorensen AM, Perner A, et al. Platelet aggregation following trauma: a prospective study. Blood Coagul Fibrinolysis. 2014;25(1):67–73.
62. Wohlauer MV, Moore EE, Droz NM, et al. Hemodilution is not critical in the pathogenesis of the acute coagulopathy of trauma. J Surg Res. 2012;173(1):26–30.
63. Wohlauer MV, Moore EE, Thomas S, et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 2012;214(5):739–746.
64. Castellino FJ, Chapman MP, Donahue DL, et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. J Trauma Acute Care Surg. 2014;76(5):1169–1176.
65. Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg. 2011;254(1):10–19.
66. Park MS, Owen BA, Ballinger BA, et al. Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity, while standard markers are not. Surgery. 2012;151(6):831–836.
67. Park MS, Xue A, Spears GM, et al. Thrombin generation and proco-agulant microparticle profiles after acute trauma: a prospective cohort study. J Trauma Acute Care Surg. 2015;79(5):726–731.
68. Matijevic N, Wang YW, Wade CE, et al. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res. 2014;134(3):652–658.
69. Tian Y, Salsbery B, Wang M, et al. Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood. 2015;125(13):2151–2159.
70. Nekludov M, Mobarrez F, Gryth D, Bellander BM, Wallen H. Formation of microparticles in the injured brain of patients with severe isolated traumatic brain injury. J Neurotrauma. 2014;31(23):1927–1933.
71. Zhang Q, Raoof M, ChenY, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–107.
72. Johansson PI, Windelov NA, Rasmussen LS, Sorensen AM, Ostrowski SR. Blood levels of histone-complexed DNA fragments are associated with coagulopathy, inflammation and endothelial damage early after trauma. J Emerg Trauma Shock. 2013;6(3):171–175.
73. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13(6):R174.
74. Giannoudis PV, Mallina R, Harwood P, Perry S, Sante ED, Pape HC. Pattern of release and relationship between HMGB-1 and IL-6 following blunt trauma. Injury. 2010;41(12):1323–1327.
75. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003;254(4):375–385.
76. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth. 2008;100(6):792–797.
77. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma. 2009;67(1):125–131.
78. Schochl H, Voelckel W, Maegele M, Solomon C. Trauma-associated hyperfibrinolysis. Hamostaseologie. 2012;32(1):22–27.
79. Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015;13(Suppl 1):S98–105.
80. Cotton BA, Harvin JA, Kostousouv V, et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73(2):365–370.
81. Chapman MP, Moore EE, Moore HB, et al. The “Black Diamond”: Rapid thrombelastography identifies lethal hyperfibrinolysis. J Trauma Acute Care Surg. 2015;79(6):925–929.
82. Allard S, Green L, Hunt BJ. How we manage the haematological aspects of major obstetric haemorrhage. Br J Haematol. 2014;164(2):177–188.
83. Johansson P, Stensballe J, Ostrowski S. Shock induced endotheliopa-thy (SHINE) in acute critical illness-a unifying pathophysiologic mechanism. Crit Care. 2017;21(1):25.
84. White NJ, Ward KR, Pati S, Strandenes G, Cap AP. Hemorrhagic blood failure: oxygen debt, coagulopathy, and endothelial damage. J Trauma Acute Care Surg. 2017;82(6S Suppl 1):S41–S49.
85. Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012;73(1):60–66.
86. Johansson PI, Ostrowski SR. Acute coagulopathy of trauma: balancing progressive catecholamine induced endothelial activation and damage by fluid phase anticoagulation. Med Hypotheses. 2010;75(6):564–567.
87. Hayakawa M, Gando S, Ono Y, Wada T, Yanagida Y, Sawamura A. Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma: a retrospective observational study. Semin Thromb Hemost. 2015;41(1):35–42.
88. Hayakawa M, Sawamura A, Gando S, et al. Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. Surgery. 2011;149(2):221–230.
89. Yanagida Y, Gando S, Sawamura A, et al. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery. 2013;154(1):48–57.
90. Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41(6):514–521.
91. Cardenas JC, Wade CE, Holcomb JB. Mechanisms of trauma-induced coagulopathy. Curr Opin Hematol. 2014;21(5):404–409.
92. Chapman MP, Moore EE, Ramos CR, et al. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg. 2013;75(6):961–967.
93. Moore HB, Moore EE, Huebner BR, et al. Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator. J Trauma Acute Care Surg. 2017;83(6):1014–1022.
94. Davenport R. Pathogenesis of acute traumatic coagulopathy. Transfusion. 2013;53(Suppl 1):23S–27S.
95. Raza I, Davenport R, Rourke C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2):307–314.
96. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32.
97. Moore HB, Moore EE, Gonzalez E, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811–817.
98. Alam AQ. Use of TXA to Prevent Postpartum Hemorrhage (TAPPH-1). Available from: https://clinicaltrials.gov/ct2/show/NCT03069859?ter m=NCT03069859&rank=1. Accessed May 18, 2018.
99. Shakur H. Haemorrhage Alleviation With Tranexamic Acid-Intestinal System (HALT-IT); NCT01658124. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT01658124?term=HALT-IT&rank=1. Accessed May 5, 2018.
100. Panteli M, Pountos I, Giannoudis PV. Pharmacological adjuncts to stop bleeding: options and effectiveness. Eur J Trauma Emerg Surg. 2016;42(3):303–310.
101. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342–1351.
102. Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med. 2016;7:217–225.
103. Hagemo JS, Stanworth S, Juffermans NP, et al. Prevalence, predic-tors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care. 2014;18(2):R52.
104. vanDeWater L, Carr JM, Aronson D, McDonagh J. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood. 1986;67(5):1468–1473.
105. Martini J, Maisch S, Pilshofer L, Streif W, Martini W, Fries D. Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs. Transfusion. 2014;54(1):149–157.
106. Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma. 2009;67(1):202–208.
107. Hunt BJ, Segal H. Hyperfibrinolysis. J Clin Pathol. 1996;49(12):958.
108. Stachurska J, Latallo Z, Kopec M. Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP). Thromb Diath Haemorrh. 1970;23(1):91–98.
109. Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion. 2013;53(5):1120–1131.
110. Andreason CL, Pohlman TH. Damage control resuscitation for catastrophic bleeding. Oral Maxillofac Surg Clin North Am. 2016;28(4):553–568.
111. Papadopoulos D, Siempis T, Theodorakou E, Tsoulfas G. Hepatic ischemia and reperfusion injury and trauma: current concepts. Arch Trauma Res. 2013;2(2):63–70.
112. Satterly SA, Martin M, Wingerd M, Hempel J, Hoffer Z, Stallings JD. Flutamide fails to reduce resuscitation requirements in a porcine ischemia-reperfusion model. J Surg Res. 2013;184(1):472–479.
113. Singer M. Critical illness and flat batteries. Crit Care. 2017;21(Suppl 3):309.
114. Waxman K. Shock: ischemia, reperfusion, and inflammation. New Horiz. 1996;4(2):153–160.
115. Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med. 2017;23(3):279–287.
116. Raymond SL, Holden DC, Mira JC, et al. Microbial recognition and danger signals in sepsis and trauma. Biochim Biophys Acta. 2017;1863(10 Pt B):2564–2573.
117. Wagner N, Dieteren S, Franz N, et al. Ethyl pyruvate ameliorates hepatic injury following blunt chest trauma and hemorrhagic shock by reducing local inflammation, NF-kappaB activation and HMGB1 release. PLoS One. 2018;13(2):e0192171.
118. Eppensteiner J, Davis RP, Barbas AS, Kwun J, Lee J. Immunothrom-botic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults. Front Immunol. 2018;9:190.
119. Levy RM, Mollen KP, Prince JM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1538–R1544.
120. Eskici ZM, Acikgoz S, Piskin N, et al. High mobility group B1 levels in sepsis and disseminated intravascular coagulation. Acta Biochim Pol. 2012;59(4):561–566.
121. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94(5):975–979.
122. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38(2 Suppl):S35–S42.
123. Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5(1):109–116.
124. Zettel KR, Dyer M, Raval JS, et al. Aged human stored red blood cell supernatant inhibits macrophage phagocytosis in an HMGB1 dependent manner after trauma in a murine model. Shock. 2017;47(2):217–224.
125. Thurairajah K, Briggs GD, Balogh ZJ. The source of cell-free mitochondrial DNA in trauma and potential therapeutic strategies. Eur J Trauma Emerg Surg. Epub 2018. April 9.
126. Nakahira K, Kyung SY, Rogers AJ, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 2013;10(12):e1001577.
127. Black GE, Sokol KK, Moe DM, et al. Impact of a novel phosphoino-sitol-3 kinase inhibitor in preventing mitochondrial DNA damage and damage-associated molecular pattern accumulation: results from the Biochronicity Project. J Trauma Acute Care Surg. 2017;83(4):683–689.
128. McNab A, Burns B, Bhullar I, Chesire D, Kerwin A. A prehospital shock index for trauma correlates with measures of hospital resource use and mortality. Surgery. 2012;152(3):473-476.
129. Mitra B, Fitzgerald M, Chan J. The utility of a shock index ≥1 as an indication for pre-hospital oxygen carrier administration in major trauma. Injury. 2014;45(1):61–65.
130. Mutschler M, Nienaber U, Munzberg M, et al. The Shock Index revisited-a fast guide to transfusion requirement? A retrospective analysis on 21,853 patients derived from the TraumaRegister DGU(R). Crit Care. 2013;17(4):R172.
131. Camazine MN, Hemmila MR, Leonard JC, et al. Massive transfusion policies at trauma centers participating in the American College of Surgeons Trauma Quality Improvement Program. J Trauma Acute Care Surg. 2015;78(6 Suppl 1):S48–53.
132. Tonglet ML. Early Prediction of Ongoing Hemorrhage in Severe Trauma: Presentation of the Existing Scoring Systems. Arch Trauma Res. 2016;5(4):e33377.
133. Arakaki LSL, Bulger EM, Ciesielski WA, et al. Muscle oxygenation as an early predictor of shock severity in trauma patients. Shock. 2017;47(5):599–605.
134. Schenkman KA, Carlbom DJ, Bulger EM, et al. Muscle oxygenation as an indicator of shock severity in patients with suspected severe sepsis or septic shock. PLoS One. 2017;12(8):e0182351.
135. Schenkman KA, Hawkins DS, Ciesielski WA, Delaney M, Arakaki LS. Non-invasive assessment of muscle oxygenation may aid in optimis-ing transfusion threshold decisions in ambulatory paediatric patients. Transfus Med. 2017;27(1):25–29.
136. Arakaki LS, Schenkman KA, Ciesielski WA, Shaver JM. Muscle oxygenation measurement in humans by noninvasive optical spectroscopy and locally weighted regression. Anal Chim Acta. 2013;785:27–33.
137. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–482.
138. Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2017;25(1):39.
139. Lopez E, Srivastava AK, Pati S, Holcomb JB, Wade CE. Platelet-derived microvesicles: a potential therapy for trauma-induced coagulopathy. Shock. 2018;49(3):243–248.
140. Hickman DA, Pawlowski CL, Sekhon UDS, Marks J, Gupta AS. Biomaterials and advanced technologies for hemostatic management of bleeding. Adv Mater. 2018;30(4):1700859.
141. Centers for Disease C, Prevention. Fatal bacterial infections associated with platelet transfusions--United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54(7):168–170.
142. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017;7:CD009072.
143. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion. 2009;49(12):2743–2758.
144. Acker JP, Marks DC, Sheffield WP. Quality assessment of established and emerging blood components for transfusion. J Blood Transfus. 2016;2016:4860284.
145. Neisser-Svae A, Trawnicek L, Heger A, Mehta T, Triulzi D. Five-day stability of thawed plasma: solvent/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours. Transfusion. 2016;56(2):404–409.
146. Hess JR, Holcomb JB. Resuscitating PROPPRly. Transfusion. 2015;55(6):1362–1364.
147. Mayr WR. Haemovigilance: are there significant differences among plasma products? Transfus Apher Sci. 2010;43(3):407–409.
148. Pitkanen H, Jouppila A, Mowinckel MC, et al. Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. Thromb Res. 2015;135(1):167–174.
149. Heger A, Neisser-Svae A, Trawnicek L, Triulzi D. Thrombin generation potential and clot-forming capacity of thawed fresh-frozen plasma, plasma frozen within 24 h and solvent/detergent-treated plasma (octaplasLG((R))), during 5-day storage at 1-6 degrees C. Vox Sang. Epub 2018 April 23.
150. USFDA. Available from: 2018;https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/ucm336161.pdf. Accessed May 18, 2018.
151. Chhibber V, Greene M, Vauthrin M, Bailey J, Weinstein R. Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME). Transfusion. 2014;54(7):1751–1755.
152. Cooling L. Going from A to B: the safety of incompatible group A plasma for emergency release in trauma and massive transfusion patients. Transfusion. 2014;54(7):1695–1697.
153. Mehr CR, Gupta R, von Recklinghausen FM, Szczepiorkowski ZM, Dunbar NM. Balancing risk and benefit: maintenance of a thawed Group A plasma inventory for trauma patients requiring massive transfusion. J Trauma Acute Care Surg. 2013;74(6):1425–1431.
154. Winearls J, Campbell D, Hurn C, et al. Fibrinogen in traumatic haemorrhage: a narrative review. Injury. 2017;48(2):230–242.
155. Winearls J, Wullschleger M, Wake E, et al. Fibrinogen Early In Severe Trauma studY (FEISTY): study protocol for a randomised controlled trial. Trials. 2017;18(1):241.
156. Okerberg CK, Williams LA 3rd, Kilgore ML, et al. Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients-an economic evaluation. Vox Sang. 2016;111(3):292–298.
157. Kriebardis AG, Antonelou MH, Georgatzakou HT, Tzounakas VL, Stamoulis KE, Papassideri IS. Microparticles variability in fresh frozen plasma: preparation protocol and storage time effects. Blood Transfus. 2016;14(2):228–237.
158. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood. 1988;71(5):1361–1365.
159. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke. 2002;33(6):1618-1623.
160. Karkouti K, von Heymann C, Jespersen CM, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg. 2013;146(4):927–939.
161. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922–934.
162. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370(9585):439–-448.
163. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69(3):489–500.
164. Murthi SB, Stansbury LG, Dutton RP, Edelman BB, Scalea TM, Hess JR. Transfusion medicine in trauma patients: an update. Expert Rev Hematol. 2011;4(5):527–537.
165. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162–174.
166. McCarron DA, Elliott WC, Rose JS, Bennett WM. Severe mixed metabolic acidosis secondary to rhabdomyolysis. Am J Med. 1979;67(5):905–908.
167. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6(5):274–285.
168. Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004;56(6):1221–1228.
169. Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood. 1999;94(1):199–207.
170. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31(10):2450–2455.
171. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg. 2014;76(2):255–263.
172. Asehnoune K, Balogh Z, Citerio G, et al. The research agenda for trauma critical care. Intensive Care Med. 2017;43(9):1340–1351.
173. Shukla M, Sekhon UD, Betapudi V, et al. In vitro characterization of SynthoPlate (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice. J Thromb Haemost. 2017;15(2):375–387.
174. Harr JN, Moore EE, Ghasabyan A, et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013;39(1):45–49.
175. Jeger V, Willi S, Liu T, et al. The Rapid TEG a-Angle may be a sensitive predictor of transfusion in moderately injured blunt trauma patients. ScientificWorldJournal. 2012;2012:821794.
176. Jeger V, Zimmermann H, Exadaktylos AK. Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? J Trauma. 2009;66(4):1253–1257.
177. Schlimp CJ, Solomon C, Ranucci M, Hochleitner G, Redl H, Schochl H. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in throm-boelastometry. Anesth Analg. 2014;118(2):269–276.
178. Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg. 2010;251(4):604–614.
179. Kashuk JL, Moore EE, Wohlauer M, et al. Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. Transfusion. 2012;52(1):23–33.
180. Pommerening MJ, Goodman MD, Farley DL, et al. Early diagnosis of clinically significant hyperfibrinolysis using thrombelastography velocity curves. J Am Coll Surg. 2014;219(6):1157–1166.
181. Sheen JH, Heeger PS. Effects of complement activation on allograft injury. Curr Opin Organ Transplant. 2015;20(4):468–475.
182. Davis AE 3rd, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008;45(16):4057–4063.